New Edinburgh dog park set to open with host of activities in place for pooches
Situated close to the Highland Show ground just off the A8 at Gogarburn, the space is billed as the perfect area for dog owners and professional walkers to have fun with their pooches.
The site has been launched by Unleash The Dogs and will open on Saturday July 5 but bookings are already open.
READ MORE: Devastated Edinburgh owners shut restaurant due to 'ridiculous' experience
READ MORE: Eager Edinburgh city centre shoppers in huge queues for fancy new jewellery shop
Another site in Edinburgh has also been earmarked for development with the company stating a space by Fort Kinnaird will also open later this summer.
Several sites have already been launched in Glasgow by Craig and his partner Lauren, who both hail from a farming background.
Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages.
The new Edinburgh site will contain a variety of obstacle equipment for dogs of all shapes and sizes to enjoy in a secure enclosed environment.
Craig, 34, said: 'This is a huge step for us. Edinburgh has a completely different layout to Glasgow, so we've worked hard to find a spot that balances that rural escapism our parks are known for, while staying easily accessible.
'The West Edinburgh field is only about a 15-minute drive from the city centre, yet it is a proper rural escape.
'We wanted to create something truly special here, not just another enclosed space but a destination for dogs and their owners.'
Owners and professional dog-walkers can book their slot for up to eight dogs at a time online, guaranteeing complete private access to the site.
The sites also benefit from regular staffing to ensure the grounds are immaculately maintained, ensuring a safe and clean experience for all visitors.
Craig added: 'Our parks are run like five-star resorts. We have regular staff visits, bespoke features, and we never cut corners.
'It's about keeping standards sky high and creating places that owners are proud to bring their dogs to.
'We've developed a strong model in Glasgow, and the response there has been phenomenal. Edinburgh deserves the same standard – and we're here to deliver it.'
Sign up for Edinburgh Live newsletters for more headlines straight to your inbox
With its premium finish and proximity to the city, the new park is set to become a favourite for dog lovers across the capital.
For more information about Unleash the Dogs, and how to book, click here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sanofi's (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan
Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Riliprubart is a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway. The treatment is designed to block a very specific part of the immune system's response. Orphan drug designation is a special status granted by regulatory bodies for medicines that target rare diseases or conditions where there is a high unmet medical need. Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. This is a significant achievement for Sanofi (NASDAQ:SNY) because, despite existing treatments, around 30% of patients do not respond adequately, leaving a significant unmet medical need. Sanofi (NASDAQ:SNY) presented 76-week long-term data from a phase 2 clinical trial at the Peripheral Nerve Society meeting in Edinburgh. The results suggest sustained efficacy and safety of Riliprubart in a broad range of CIDP patients. Management noted that two phase 3 studies are underway to further evaluate the treatment. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Diageo plc (DEO) Announces Completion of Sale of Its Shareholding in Seychelles Breweries Limited
Diageo plc (NYSE:DEO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On July 1st, Diageo plc (NYSE:DEO) announced the completion of its sale of shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited. Diageo plc (NYSE:DEO) completed the sale of its 54.4% shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited, which is a subsidiary of Mauritius-based IBL Group, for approximately $80 million. The transaction was announced on April 2, 2025. The deal reflects the company's strategic move to focus on its portfolio management and high-margin brands while maintaining a strong presence in the Indian Ocean region through licensing agreements. A close-up of bottles of whisky and other alcoholic beverages from a winery. Under the terms of the deal, although Diageo plc (NYSE:DEO) has sold its majority stake, it retains ownership of its key brands produced by Seychelles Breweries, such as Guinness and Smirnoff RTDs. These brands will continue to be produced and distributed in Seychelles under new long-term license and royalty agreements with Seychelles Breweries, ensuring ongoing collaboration. Diageo plc (NYSE:DEO) is a UK-based producer and distributor of premium alcoholic beverages. The company operates a vast portfolio of brands and has a presence in 180 countries. While we acknowledge the potential of DEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on
